Webster G, Draelos ZD, Graber E, et al. - In this prospective, 12‐week, double‐blinded study, researchers tested the effectiveness and safety of once‐daily topical minocycline gel 1% and 3% in patients with papulopustular rosacea. This investigation was carried out at 26 sites in the United States; 270 individuals with papulopustular rosacea and 12–40 inflammatory lesions were randomized to minocycline 1%, minocycline 3% or vehicle. According to results, minocycline topical gel tends to be safe and tolerable at concentrations of 1% and 3%, and both concentrations significantly reduced counts of inflammatory lesions, with a significantly larger proportion of individuals reporting IGA efficacy at week 12 in the minocycline 3% arm. Such results help further study of minocycline gel for treating papulopustular rosacea-related inflammatory lesions.